Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Switzerland’s Galderma today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...

Valmet announced on December 18, 2024, that the Board of Directors of Valmet has decided to use the authorization granted by the Annual General Meeting held on March 21, 2024, to repurchase the ...

Rare Cannabinoid Company, a leader in hemp-derived wellness products, is celebrating February Sleep Awareness Month with an exclusive Buy One, Get One 50% Off sale on all CBN ...

In addition, in the late-stage development, as you can see in the next slide, three of our in-house products, Alecensa, PiaSky, and NEMLUVIO, have achieved approvals, and including all these ...

Nemluvio (nemolizumab-ilto) Interleukin-31 receptor antagonist Treatment of adults and pediatric patients 12 years of age and older with moderate to severe atopic dermatitis in combination with ...